Asian Diabetes Outcomes Prevention Trial

Summary

The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.

Conditions

• Diabetes Mellitus
• Cardiovascular Diseases

Interventions

DRUG

Renin-angiotensin-aldosterone system inhibitors

Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.

DRUG

Beta blocker

Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.

DRUG

SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product

Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.

Sponsors & Collaborators

• Singapore General Hospital

  collaborator OTHER

• Mackay Memorial Hospital

  collaborator OTHER

• National Taiwan University Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Medanta, The Medicity, India

  collaborator OTHER

• Public Health Foundation of India

  collaborator OTHER

• Putrajaya Hospital, Malaysia

  collaborator UNKNOWN

• Universiti Teknologi Mara

  collaborator OTHER

• National Heart Centre Singapore

  lead OTHER

Principal Investigators

• Carolyn Lam Prof · National Heart Centre Singapore

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-07-01

Primary Completion

2022-06-30

Completion

2034-06-30

Countries

• Singapore

Study Locations